Form 4 for KYTX Kyverna Therapeutics, Inc.

Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-12 · accession 0001062993-24-003026 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-02-13	2024-02-12	KYTX	GILEAD SCIENCES, INC.	10%	C - Cnv Deriv	—	+3.22M	3.22M	New	—
D	2024-02-13	2024-02-12	KYTX	GILEAD SCIENCES, INC.	10%	P - Purchase	$22.00	+910.0K	4.13M	+28%	+$20.02M
DM	2024-02-13	2024-02-12	KYTX	GILEAD SCIENCES, INC.	10%	C - Cnv Deriv	$0.00	-14.64M	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-02-12	C	A	3,216,119	—	3,216,119	D	—	—	(F1) The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date. (F2) Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024.
2	Common	Common Stock	2024-02-12	P	A	910,000	$22.00	4,126,119	D	—	—
3	Derivative	Series A-2 Convertible Preferred Stock	2024-02-12	C	D	6,890,744	$0.00	0	D	— · — to —	1,514,083 Common Stock	(F1) The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.
4	Derivative	Series B Convertible Preferred Stock	2024-02-12	C	D	7,746,139	$0.00	0	D	— · — to —	1,702,036 Common Stock	(F1) The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date.